Nutriband Inc. Warrant (NASDAQ:NTRBW)

US · Delayed Price · Currency is USD

0.97+0.58 (+149.74%)

Market Cap	133.08M-50.3%
Revenue (ttm)	1.62M-37.3%
Net Income	-6.96M+32.2%
EPS	-0.57+80.1%
Shares Out	11.94M
PE Ratio	n/a
Forward PE	0.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,066
Open	2.61
Previous Close	0.39
Day's Range	0.54 - 2.61
52-Week Range	0.17 - 2.99
Beta	1.97
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

+148.72% (1D)

No price history available.

Full Chart

Alerts Compare

About NTRBW

Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system. This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.

Address

121 South Orange Avenue, Orlando, FL, 32801, US

Market Cap

133 million

Employees

Industrial Classification

Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying

Sold

Bought

$20.15K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day

+149.74%

5 Days

+62.36%

1 Month

+178.29%

6 Months

-25.08%

1 Year

-50.31%

$NTRBW stock is featured in our Insider Trades datasets.

→ All Stock Lists

Whale Activity →

Recently reported changes in NTRBW holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by NTRBW's directors and management

No SEC Form 4 activity for NTRBW in the last 5 quarters.

Source: SEC EDGAR (Form 4)

Corporate Lobbying

NTRBW Estimated quarterly lobbying spending

Source: U.S. Senate LDA

Revenue Breakdown →

NTRBW Revenue by Segment or Geography

NTRBW's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Jul 31, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New NTRBW patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to NTRBW from public contracts

Source: USAspending.gov

NTRBW Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for NTRBW yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from NTRBW’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys

Sells

Buy Value

$20.15K

Distinct Buyers

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.